The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
[EN] BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS AZAHÉTÉROCYCLIQUES BICYCLIQUES UTILISÉS COMME ANTAGONISTES DES RÉCEPTEURS NMDA NR2B
申请人:RUGEN HOLDINGS (CAYMAN) LTD
公开号:WO2016100349A3
公开(公告)日:2016-08-18
COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
申请人:Bristol-Myers Squibb Company
公开号:EP2331502A2
公开(公告)日:2011-06-15
INHIBITORS OF HEPATITIS C VIRUS
申请人:Zhong Min
公开号:US20120251497A1
公开(公告)日:2012-10-04
A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.